# ORIGINAL RESEARCH Family History of Cancers Increases Risk of Renal Cell Carcinoma in a Chinese Population

Siwei Xing <sup>1</sup>,\*, Xiaohao Ruan<sup>1</sup>,\*, Jingyi Huang<sup>1</sup>,\*, Jiaqi Yan<sup>1</sup>, Wenhao Lin<sup>1</sup>, Jinlun Huang<sup>1</sup>, Jiacheng Liu<sup>1</sup>, Da Huang<sup>1</sup>, Rong Na<sup>2</sup>, Danfeng Xu<sup>1</sup>

Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; <sup>2</sup>Division of Urology, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Rong Na, Division of Urology, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, People's Republic of China, Email narong.hs@gmail.com; Da Huang, Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025, People's Republic of China, Email huangdasjtu@gmail.com

Purpose: To explore the impact of family history (FH) on renal cell carcinoma (RCC) and its pathological subtype clear cell RCC (ccRCC) in a Chinese population; a significant association has previously been determined not only in familial cancer syndrome but also in sporadic cases in western populations.

Methods: Consecutive patients with kidney tumors from October 2017 to May 2021 at a tertiary hospital in Shanghai were enrolled in the study. Demographic and clinical information was collected, including age, gender, FH (positive or negative, types of cancers, degree of relatives, etc.), pathological diagnosis, and Fuhrman grades.

**Results:** A positive FH of any cancer was observed in 26.5% of the RCC patients, while only 16.8% patients with benign kidney tumor were found to have a positive FH. A strong correlation was observed between FH of any cancers in first-degree relatives and RCC (odds ratio [OR]=4.60, 95% confidence interval [CI]: 1.95-10.85,  $P=5.50\times10^{-5}$ ) or ccRCC (OR=4.63, 95% CI: 1.95-11.02,  $P=9.63\times10^{-5}$ ). In subgroup analysis, FH of digestive cancers was significantly associated with RCC (OR=4.42, 95% CI: 1.35–14.51, P=0.005) or ccRCC (OR=4.14, 95% CI: 1.25–13.75, P=6.84×10<sup>-4</sup>). Similar results were found in multivariate analyses. However, no significant association was observed between FH and age at onset.

Conclusion: FH was an independent risk factor for RCC and ccRCC in this Chinese population. FH of any cancer in first-degree relatives and FH of digestive cancers were found to be the most significant risk factors for kidney cancers.

Keywords: Chinese population, family history, renal cell carcinoma, risk factor, multivariate regression analysis

#### Introduction

As the seventh most common malignant carcinoma worldwide, the incidence of kidney cancer has been increasing rapidly over the past few years.<sup>1</sup> Among the different pathological types, renal cell carcinoma (RCC) may account for over 80% of kidney cancers.<sup>2</sup> In contrast to the increased exploration of innovative treatment targets and prognostic models, knowledge on the risk factors for and predisposition to the disease has barely evolved.

Risk factors including age, gender, smoking, and alcohol intake have been found to be correlated with RCC.<sup>3–6</sup> An excess accumulation of adipose tissue, particularly visceral adipose tissue, has also been observed in the development of RCC.<sup>7-9</sup> which makes obesity another general risk factor. Although most cases are sporadically diagnosed, a family history (FH) of cancer should also be considered as a valuable factor, especially since certain genetic mutations in genes such as Von Hippel-Lindau (VHL), fumarate hydratase, and succinate dehydrogenase B have established associations with RCC.<sup>10-12</sup>

In addition, a positive FH in relatives of RCC patients may be associated with disease onset and outcome. For example, sequential research from the Swedish public health service found that patients with a positive FH had a 4.58-fold higher risk (95% confidence interval [CI]: 2.87-6.94) of RCC and could also suffer from subsequent cancer after the onset of RCC.<sup>13,14</sup> Studies regarding the association between FH and RCC risk have mostly focused

on western populations.<sup>4,13</sup> Unfortunately, related research based on an eastern population, such as Japanese<sup>15</sup> or Korean,<sup>16</sup> focused on genotyping and genetic mutations and did not provide explicit data on patients' epidemiological features.

To our knowledge, no similar study has been published based on a Chinese population to date. This prompted us to explore the association between FH and the clinical onset of RCC and provide evidence for risk evaluation in affected individuals. In the present study, we evaluated the association between FH of different types of kidney cancers at different levels of relatives and the risk of RCC, using a consecutive surgical cohort, in Chinese patients.

# **Patients and Methods**

#### Study Population and Study Design

This is a retrospective study based on a group of consecutive patients with kidney tumors undergoing partial or radical surgery from October 2017 to May 2021 at Ruijin Hospital, a tertiary hospital in Shanghai, China. The study was approved by the institutional review board of Shanghai Ruijin Hospital (central IRB no. KY2016-343, 24 Nov 2016, version 03), and written informed consent was obtained from each participant. Patients were excluded from the present study if they were uncertain about either the type of cancer of a positive FH or the overall situation of the FH of cancer.

A total of 484 cases were finally included in the present study. To ensure data integrity and legitimacy, FH of cancers was collected by investigators through a structured questionnaire (positive or negative, types of cancers, degree of relatives, etc.).

A first-degree FH was defined as having direct blood relatives with a cancer history. FH of digestive cancers was defined as positive FH of gastric and colonic cancers. Other detailed demographic and clinical information was collected before and after surgery, including age, gender, pathological diagnosis, and Fuhrman grades.

All surgical specimens were independently examined and graded by two experienced pathologists. Carcinoma of Fuhrman grade 1–2 was defined as the low-grade group, while that of Fuhrman grade 3–4 was defined as the high-grade group.<sup>17,18</sup>

#### Statistical Analyses

The chi-squared test or Fisher's exact test was used in univariable analysis for categorical variables. Multivariable logistic regression analysis was conducted to further evaluate the associations. Survival analysis for disease-free survival (age at onset) was evaluated by the log-rank test (Kaplan–Meier). A two-tailed P<0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism (version 6.00 for Windows, GraphPad Software) and SPSS Statistics (IBM Corp., IBM SPSS Statistics for Windows, version 24.0, released 2016).

# Results

# Demographic Observation Revealed a Higher Co-Morbidity of Positive FH with RCC

Demographic characteristics and baseline information of the study cohort are shown in Table 1. Among 484 cases, 389 (80.4%) were pathologically diagnosed as RCC, and the rest were diagnosed as benign tumors, such as complicated renal cyst, angiomyolipoma, or oncocytoma. Of the patients with RCC, 311 were diagnosed as clear cell renal cell carcinoma (ccRCC), which accounted for 79.9% of all RCC. Detailed information on the subtypes of RCC is presented in Table 2. The median age of the patients was 57 years (interquartile range [IQR]: 14–89 years).

A positive FH of any cancer was observed in 26.5% of the RCC patients (26.0% of ccRCC), while only 16.8% patients with a benign kidney tumor were found to have a positive FH (Table 1). Further stratification analyses discovered that most of the positive FHs presented in a first-degree relative (98 out of 119, 82.4%). Regarding types of cancers, seven cases of RCC (1.8% positive rate) had a positive FH of RCC, six of whom were ccRCC patients (1.9% positive rate), while none of the patients with a benign kidney tumor had a positive FH of RCC (Table 3). Digestive cancers were established as the most frequent co-morbidity.

Variables	Total	R	Non-Carcinoma*	
		All RCC	ccRCC	-
Total	484	389	311	95
Gender				
Male, n (%)	299	262 (67.4%)	213 (68.5%)	37 (38.9%)
Female, n (%)	189	127 (32.6%)	98 (31.5%)	58 (61.1%)
Age (years), median (IQR)	57 (14–89)	58 (25–84)	59 (30-84)	53 (14–89)
≥50, n (%)	360	301 (77.4%)	246 (79.1%)	59 (62.1%)
<50, n (%)	124	88 (22.6%)	65 (20.9%)	36 (37.9%)
FH of any cancer				
Yes, n (%)	119	103 (26.5%)	81 (26.0%)	16 (16.8%)
No, n (%)	365	286 (73.5%)	230 (74.0%)	79 (83.2%)
Grade (Fuhrman)				
I	31	31	28	-
2	240	240	212	-
3	65	65	53	-
4	19	19	17	-

Table I Demographic Characteristics and Baseline Info	ormation of the Study Cohort
---	------------------------------

Note: \*Non-carcinoma: benign pathological diagnosis.

Abbreviations: RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; FH, family history.

RCC	Benign Pathological Diagnosis		
Diagnosis	Cases	Diagnosis	Cases
ccRCC	311	Angiomyolipoma	47
Papillary RCC (pRCC)	40	Complicated cyst	35
Unclassifiable RCC	18	Oncocytoma	10
ccRCC combined with pRCC	6	Lipoma	2
Chromophobe RCC	5	Metanephric adenoma	I
RCC associated with Xp11.2 translocations/TFE3 gene fusions	4		
Mucinous tubular and spindle cell renal carcinoma	I		
Leiomyosarcoma	I		
Sarcomatoid carcinoma	I		
Biphasic squamoid alveolar RCC	I		
RCC with leiomyomatous stroma	L		
Total	389	Total	95

 Table 2 Subtype Information of RCC and Benign Pathological Diagnosis

Abbreviations: RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; pRCC, papillary renal cell carcinoma.

# FH Could Be Considered as an Independent Risk Factor for RCC

We then set out to evaluate the influence of FH on RCC incidence, and notably the most common pathological type, ccRCC.

FH of any cancers increased the risk of RCC (odds ratio [OR]=1.78, 95% CI: 0.99–3.19, P=0.062) and ccRCC (OR=1.74, 95% CI: 0.96–3.15, P=0.074) (Table 3) at marginally significant levels. The percentages of RCC patients and ccRCC patients with a positive FH of any cancer in first-degree relatives were 23.7% (OR=4.60, 95% CI: 1.95–10.85, P=5.50×10<sup>-5</sup>) and 23.8% (OR=4.63, 95% CI: 1.95–11.02, P=9.63×10<sup>-5</sup>), respectively, which were significantly higher than those in patients with benign tumors (6.3%) (Table 3). These results indicate that a positive FH in first-degree relatives may be a risk factor for RCC and ccRCC.

Variables	Total	RCC		Non-Carcinoma (n=95)	All RCC vs Non-Carcinoma		ccRCC vs Non-Carcinoma	
		All RCC (n=389)	ccRCC (n=311)		OR (95% CI)	P-Value	OR (95% CI)	P-Value
FH of any cancers	119	103 (26.5%)	81 (26.1%)	16 (16.9%)	1.78 (0.99–3.19)	0.062	1.74 (0.96–3.15)	0.074
FH of any cancers in first-degree relatives, n (%)	98	92 (23.7%)	74 (23.8%)	6 (6.3%)	4.60 (1.95–10.85)	5.50×10 <sup>-5</sup>	4.63 (1.95–11.02)	9.63×10 <sup>-5</sup>
FH of cancers in different systems								
FH of digestive cancers	52	49 (12.6%)	37 (11.9%)	3 (3.2%)	4.42 (1.35–14.51)	0.005	4.14 (1.25–13.75)	6.84×10 <sup>-4</sup>
FH of pulmonary cancers	29	26 (6.7%)	21 (6.8%)	3 (3.2%)	2.20 (0.65-7.42)	0.24	2.22 (0.65–7.62)	0.32
FH of RCC	7	7 (1.8%)	6 (1.9%)	0 (0.0%)	2.62 (0.14-48.1)	0.59	2.84 (0.15–53.00)	0.59
FH of other cancers	31	21 (5.4%)	17 (5.5%)	10 (10.5%)	0.15 (0.05–0.47)	0.001	0.16 (0.05–0.50)	0.002

Table 3 Association Between Family History and RCC

Abbreviations: RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; FH, family history.

We then evaluated whether a positive FH of specific types of cancers could be associated with the risk of RCC or ccRCC. We observed that 12.6% of the RCC patients (OR=4.42, 95% CI: 1.35–14.51, P=0.005) and 11.9% of the ccRCC patients (OR=4.14, 95% CI: 1.25–13.75, P=6.84×10<sup>-4</sup>) had a positive FH of digestive cancers, which was significantly higher than in patients with benign tumors (3.2%) (Table 3). No association was observed between FH of other specific cancer types and RCC or ccRCC.

To further examine whether FH could be an independent risk factor for RCC, we performed multivariate logistic regression analyses adjusting for gender and age (Table 4). The results suggested that FH of any cancer was independently and significantly associated with RCC (OR=1.85, 95% CI: 1.01-3.37, P=0.045). This association was even stronger in patients with a positive FH in first-degree relatives (OR=4.36, 95% CI: 1.83-10.42, P=0.001). In addition, a positive FH of digestive cancers was an independent risk factor for RCC (OR=4.02, 95% CI: 1.21-13.36, P=0.023). We discovered that their influence was also significant in the sole pathological type ccRCC (Table 4).

#### FH Did Not Share an Association with Age at Onset or Pathological Grading

Next, we investigated whether FH could also serve as a prognostic indicator. We employed the following two common factors for assessment: pathological grading and age at onset of the disease.

We performed multivariate logistic regression analysis to evaluate the influence of FH on prediction of pathological grades. However, after adjustment for gender and age, no significant association was observed between FH and high Fuhrman grade (grade 3–4) of RCC (Table 4).

We then analyzed the association between FH and age at onset. No significant association was found between early age at onset (<50 years), a potential indicator of poorer prognosis, and FH (all *P*>0.05) (Table 5) through Kaplan–Meier

Variables	RCC vs Non-Carcinoma		ccRCC vs Non-Carcinoma		Low Grade (1–2) vs High Grade (3–4)	
	OR (95% CI)	P-Value	OR (95% CI)	P-Value	OR (95% CI)	P-value
Gender	3.34 (2.09–5.32)	<0.001	3.48 (2.14–5.66)	<0.001	2.25 (1.23-4.13)	0.009
Age (≥50 years)	2.08 (1.27-3.40)	0.003	2.38 (1.41–4.00)	0.001	3.72 (1.63-8.50)	0.002
FH of any cancers*	1.85 (1.01–3.37)	0.045	1.90 (1.03–3.53)	0.041	0.73 (0.40-1.35)	0.314
FH of any cancers in first-degree relatives*	4.36 (1.83–10.42)	0.001	4.76 (1.96–11.52)	0.001	0.79 (0.42-1.45)	0.441
FH of digestive cancers*	4.02 (1.21–13.36)	0.023	3.69 (1.10–12.43)	0.035	0.77 (0.35–1.71)	0.522

Table 4 Multivariate Logistic Regression Analyses Evaluating the Association Between FH and RCC

Note: \*Adjusted for gender and age category.

Abbreviations: FH, family history; RCC, renal cell carcinoma.

Age (Years)	Total	FH		FH in First-D	egree Relatives	FH of Digestive Cancers		
		Positive	Negative	Positive	Negative	Positive	Negative	
RCC patients								
≥50, n (%)	301	73 (70.9%)	228 (79.7%)	72 (78.3%)	229 (77.1%)	36 (76.6%)	263 (77.4%)	
<50, n (%)	88	30 (29.1%)	58 (20.3%)	20 (21.7%)	68 (22.9%)	11 (23.4%)	77 (22.6%)	
P-value		0.075		0.89		0.86		
ccRCC patients								
≥50, n (%)	246	58 (71.6%)	188 (81.7%)	57 (77.0%)	189 (79.7%)	29 (78.4%)	217 (79.2%)	
<50, n (%)	65	23 (28.4%)	42 (18.3%)	17 (23.0%)	48 (20.3%)	8 (21.6%)	57 (20.8%)	
P-value		0.058		0.63		1.00		

Table 5 Association Between FH and Age at Onset

Abbreviations: FH, family history; RCC, renal cell carcinoma, ccRCC, clear cell renal cell carcinoma.

analyses. Moreover, survival analyses did not find any significant link between FH and age at onset (all P>0.05) (Figure 1A–F).

#### Discussion

This is the first time that the association between FH and RCC has been evaluated in a Chinese population. We found that:<sup>1</sup> FH of any cancers was a risk factor for RCC and ccRCC;<sup>2</sup> FH of any cancers in first-degree relatives and FH of digestive cancers were stronger risk factors for RCC and ccRCC;<sup>3</sup> and FH was not associated with pathological grade (Fuhrman grade) or age at onset (early onset). Significant correlations are summarized and visualized in Figure 2.

Our findings are consistent with those of previously published results from other countries in people of other ethnicities.<sup>4,13,16</sup> However, the importance of positive FH in patients with renal tumors has not yet been discussed thoroughly. Most of the related literature focused on hereditary patterns of RCC types, such as VHL disease,<sup>19</sup> hereditary papillary RCC,<sup>11</sup> and hereditary leiomyomatosis.<sup>16,20</sup> In our study, we did not come across many familial cases of RCC,






Figure I Results of Kaplan–Meier survival analyses: (A) association between FH of all cancer and age at onset of RCC; (B) association between FH in first-degree relatives and age at onset of RCC; (C) association between FH of digestive cancer and age at onset of RCC; (D) association between FH of all cancer and age at onset of ccRCC; (E) association between FH in first-degree relatives and age at onset of ccRCC; (F) association between FH of digestive cancer and age at onset of ccRCC. *P*-values obtained by log-rank test. HR obtained by log-rank test, with 95% CI in parentheses.

Abbreviations: FH, family history; RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; HR, hazard ratio; Cl, confidence interval.





Abbreviations: FH, family history; RCC, renal cell carcinoma; OR, odds ratio; CI, confidence interval.

although all positive FHs of RCC were found in patients with malignant renal tumors. Instead, we established that FH is an independent risk factor for RCC.

Unlike for other cancers, a positive FH did not have an influence on age at onset. For example, a positive FH of prostate cancer (PCa) or BRCA-related cancers was related to an earlier age at onset of PCa.<sup>21</sup> Besides, FH of colorectal cancer (CRC) was also considered to be associated with early-onset CRC (age <50 years).<sup>22</sup> The unusual discovery in this study of RCC has not been reported in any other epidemiological research, to our knowledge.

The positive association of first-grade-relative FH with RCC was easy to interpret considering that genetic or epigenetic modifications are more likely to be passed on to the patient. We also observed that most of the FH (~90%) was in first-degree relatives. This could be due to the family planning (one-child) policy in China in the past decades that limited the size of the family.<sup>23</sup> This could lead to a lack of second-degree relatives. Another possible reason could be the poor medical infrastructure, absence of disease registration, and insufficient vital statistics before the 2000s,<sup>24</sup> which made it difficult for people and medical workers to capture information on FH (people died without the exact reason being known).

Our results also showed FH of digestive cancers to be a significant risk factor for RCC in this Chinese population. Several reviews mentioned an observational link between gastrointestinal stromal tumor and onset of RCC, indicating the potential predisposition syndromes and advocating clinical phenotyping and characterization of genotypic features.<sup>25,26</sup> Familial digestive cancers are likely to be related to Lynch syndrome, sharing a close link with malfunction of mismatch repair (MMR) genes in the DNA repair process.<sup>27–29</sup> Evidence also showed that expression of MMR genes was downregulated in RCC<sup>30</sup> and specific gene expression was related only in ccRCC.<sup>31</sup> However, whether MMR gene mutations are associated with RCC in the Chinese population is still unknown, and is worthy of further investigation given the relatively high incidence of digestive cancers in China. Another speculation could arise from the fact that obesity, and specifically the accumulation of adipose tissue in individuals, is considered a risk factor for both RCC and CRC,<sup>9,32</sup> and investigations at a molecular level may be required to confirm this.

Our study has several limitations. First, as this was a single-center retrospective study, our results may not represent the entire Chinese population. However, as this center is a tertiary hospital in Shanghai, people from all over the country come here to seek its services. Secondly, the number of cases was relatively small in the present study, because we only included

cases with a concrete demographic FH, which was collected through clinical interview. This may have introduced an inevitable bias of omission and also resulted in a limited statistical power to observe some potential differences, for instance, the relationship between FH and age at onset. Nevertheless, our study provides the first evidence on this topic based on a Chinese population. Further research in a larger population and necessary improvement of the study design, such as confirmation of the FH by histopathological examination, may help to advance and augment the findings of our study.

# **Abbreviations**

FH, family history; RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; OR, odds ratio; CI, confidence interval; IQR, interquartile rage; MMR, mismatch repair; IRB, institutional review board.

# **Data Sharing Statement**

The data and materials generated and analyzed during the current study are available from Dr. Rong Na on reasonable request.

# **Ethics Approval**

The research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, and the relevant institutional review board (IRB) at Ruijin Hospital approved the study.

# **Consent to Participate**

Informed consent was obtained from all individual participants included in the study.

#### **Consent for Publication**

The patients or parent/guardian/next of kin (in the case of minors or deceased patients) provided written informed consent for the publication of any data and/or accompanying images.

# Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (81772741, 81972405, and 81972645), Shanghai Youth Talent Support Program, and the Shanghai Sailing Program (22YF1440500).

#### Disclosure

The authors have no relevant financial or non-financial interests to disclose.

# References

- 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
- Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:804–834. doi:10.6004/jnccn.2017.0100
- 3. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11:79-87. doi:10.14740/wjon1279
- 4. Christensen MB, Wadt K, Jensen UB, et al. Exploring the hereditary background of renal cancer in Denmark. *PLoS One*. 2019;14:e0215725. doi:10.1371/journal.pone.0215725
- Gansler T, Fedewa SA, Flanders WD, Pollack LA, Siegel DA, Jemal A. Prevalence of cigarette smoking among patients with different histologic types of kidney cancer. *Cancer Epidemiol Biomarkers Prev.* 2020;29:1406–1412. doi:10.1158/1055-9965.EPI-20-0015
- Washio M, Mori M, Mikami K, et al. Risk factors for renal cell carcinoma in a Japanese population. Asian Pac J Cancer Prev. 2014;15:9065–9070. doi:10.7314/APJCP.2014.15.21.9065
- Greco F, Cirimele V, Mallio C, Zobel B, Grasso R. Increased visceral adipose tissue in male patients with clear cell renal cell carcinoma. *Clin Cancer Investig J.* 2018;7(4):132. doi:10.4103/ccij.ccij\_62\_18
- 8. Greco F, Mallio CA, Grippo R, et al. Increased visceral adipose tissue in male patients with non-clear cell renal cell carcinoma. *Radiol Med.* 2020;125:538–543. doi:10.1007/s11547-020-01146-6
- 9. Greco F, Quarta LG, Grasso RF, Beomonte Zobel B, Mallio CA. Increased visceral adipose tissue in clear cell renal cell carcinoma with and without peritumoral collateral vessels. *Br J Radiol*. 2020;93:20200334. doi:10.1259/bjr.20200334
- 10. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55-64. doi:10.1038/nrc3844
- 11. Verine J, Pluvinage A, Bousquet G, et al. Hereditary renal cancer syndromes: an update of a systematic review. *Eur Urol.* 2010;58:701–710. doi:10.1016/j.eururo.2010.08.031

- Woodward ER, Ricketts C, Killick P, et al. Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN. *Clin Cancer Res.* 2008;14:5925–5930. doi:10.1158/1078-0432.CCR-08-0608
- 13. Hemminki K, Li X. Age-specific familial risks for renal cell carcinoma with evidence on recessive heritable effects. *Kidney Int.* 2004;65:2298–2302. doi:10.1111/j.1523-1755.2004.00650.x
- 14. Chen T, Fallah M, Sundquist K, Liu H, Hemminki K. Risk of subsequent cancers in renal cell carcinoma survivors with a family history. Eur J Cancer. 2014;50:2108–2118. doi:10.1016/j.ejca.2014.05.003
- 15. Furuya M, Yao M, Tanaka R, et al. Genetic, epidemiologic and clinicopathologic studies of Japanese Asian patients with Birt-Hogg-Dube syndrome. *Clin Genet.* 2016;90:403–412. doi:10.1111/cge.12807
- 16. Seo JY, Ahn JY, Keam B, et al. Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients. *Ann Lab Med.* 2021;41:207–213. doi:10.3343/alm.2021.41.2.207
- 17. Delahunt B, Eble JN, Egevad L, Samaratunga H. Grading of renal cell carcinoma. Histopathology. 2019;74:4-17. doi:10.1111/his.13735
- 18. Becker A, Hickmann D, Hansen J, et al. Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma–Impact on prognosis. *Eur J Surg Oncol.* 2016;42:419–425. doi:10.1016/j.ejso.2015.09.023
- 19. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. *Clin Cancer Res.* 2006;12:7215-7220. doi:10.1158/1078-0432.CCR-06-2254
- Forde C, Lim DHK, Alwan Y, et al. Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals. Eur Urol Oncol. 2020;3:764–772. doi:10.1016/j.euo.2019.11.002
- 21. Xu Y, Huang D, Wu Y, et al. Family history is significantly associated with prostate cancer and its early onset in Chinese population. *Prostate*. 2019;79:1762–1766. doi:10.1002/pros.23900
- 22. Gausman V, Dornblaser D, Anand S, et al. Risk factors associated with early-onset colorectal cancer. *Clin Gastroenterol Hepatol.* 2020;18:2752–9 e2. doi:10.1016/j.cgh.2019.10.009
- 23. Gietel-Basten S, Han X, Cheng Y. Assessing the impact of the "one-child policy" in China: a synthetic control approach. *PLoS One.* 2019;14: e0220170. doi:10.1371/journal.pone.0220170
- 24. Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. *Lancet Oncol.* 2020;21:e342-e9. doi:10.1016/S1470-2045(20)30073-5
- Przybycin CG, Magi-Galluzzi C, McKenney JK. Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens. Adv Anat Pathol. 2013;20:245–263. doi:10.1097/PAP.0b013e318299b7c6
- 26. Agaimy A, Hartmann A. Uncovering hereditary tumor syndromes: emerging role of surgical pathology. Semin Diagn Pathol. 2018;35:154–160. doi:10.1053/j.semdp.2018.01.001
- 27. Sinicrope FA. Lynch syndrome-associated colorectal cancer. N Engl J Med. 2018;379:764–773. doi:10.1056/NEJMcp1714533
- 28. Biller LH, Syngal S, Yurgelun MB. Recent advances in Lynch syndrome. Fam Cancer. 2019;18:211-219. doi:10.1007/s10689-018-00117-1
- 29. Pellat A, Netter J, Perkins G, et al. Syndrome de Lynch : quoi de neuf? [Lynch syndrome: what is new?]. *Bull Cancer*. 2019;106:647–655. French. doi:10.1016/j.bulcan.2018.10.009
- 30. Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, Dahiya R. DNA mismatch repair genes in renal cell carcinoma. J Urol. 2003;169:2365–2371. doi:10.1097/01.ju.0000065668.19267.b4
- Stoehr C, Burger M, Stoehr R, et al. Mismatch repair proteins hMLH1 and hMSH2 are differently expressed in the three main subtypes of sporadic renal cell carcinoma. *Pathobiology*. 2012;79:162–168. doi:10.1159/000335642
- 32. Roslan NH, Makpol S, Mohd Yusof YA. A review on dietary intervention in obesity associated colon cancer. Asian Pac J Cancer Prev. 2019;20:1309–1319. doi:10.31557/APJCP.2019.20.5.1309

#### **Cancer Management and Research**

#### **Dove**press

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal